Drug Profile
B 0829
Latest Information Update: 12 Feb 2001
Price :
$50
*
At a glance
- Originator Yissum Research Development Company
- Class Anti-ischaemics; Antihyperglycaemics; Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases; Diabetic retinopathy; Ischaemic heart disorders
Most Recent Events
- 12 Feb 2001 Profile reviewed but no significant changes made
- 08 Sep 1998 Profile reviewed
- 08 Sep 1998 No-Development-Reported for Cancer metastases in Israel (Unknown route)